Gene therapy

BioTools Innovator Names GenNext Technologies The 2022 Winner

Retrieved on: 
Monday, October 24, 2022
Professional Services, Health, Start-Up, Research, Science, Pharmaceutical, Biotechnology, LinkedIn, Feedback, Growth, RCT, Cell, Drug development, Twitter, Program, HOS, Research Corporation, Speed Road Tour Challenge, Technology, Health, CEO, Research, Business development, Safety, Gene therapy, Prize, Accelerator, Thermo Fisher Scientific, Management, Pharmaceutical industry

BioTools Innovator , the first-ever accelerator focused on life science tools companies, announced today that GenNext Technologies is the grand prize winner of the BioTools Innovator 2022 Final competition.

Key Points: 
  • BioTools Innovator , the first-ever accelerator focused on life science tools companies, announced today that GenNext Technologies is the grand prize winner of the BioTools Innovator 2022 Final competition.
  • Congratulations to all of the BioTools Innovator 2022 cohort companies, and especially to our top winner, GenNext Technologies.
  • BioTools Innovator was launched to advance life science tools innovation and this award will help GenNext Technologies achieve its next milestone.
  • Congratulations to GenNext Technologies for receiving the title of the 2022 BioTools Innovator, said Chad Souvignier, vice president of RCT.

CMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer

Retrieved on: 
Wednesday, October 19, 2022
SAN, Parkinson, Nikon, PD, Growth, Business administration, Master of Business Administration, Neurodegeneration, GMP, Cell, Patient, Parkinson's disease, Bachelor of Science, Multimedia, Artificial intelligence, University, Good manufacturing practice, International Society, Industry, Tissue, QC, Gene therapy, Brain, Aspen, Lonza, IPSC, Kennesaw State University, Pharmaceutical industry, Management, Science

SAN DIEGO, Oct. 19, 2022 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company's executive team.

Key Points: 
  • SAN DIEGO, Oct. 19, 2022 /PRNewswire/ -- Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson's disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company's executive team.
  • "This is an important milestone for Aspen Neuroscience and Kim is an integral part of the team that will bring our products to market," said Damien McDevitt, Ph.D., president and chief executive officer.
  • Prior to joining Aspen Neuroscience, Kim served as chief manufacturing and technology officer and a member of the executive team at AVROBIO, a Boston-based leader in the gene therapy space.
  • Headquartered in San Diego, Aspen Neuroscience, Inc. is a development stage, private biotechnology company focused on personalized (autologous) cell therapies.

Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 11, 2022
Health, General Health, Lists of diseases, MENA, Vector (mathematics and physics), Geography, Severe acute respiratory syndrome coronavirus 2, Commercial, Degenerative disease, Gene, Coronavirus, Partnership, Industry, Suretrack Contracts Services, Gene therapy, USFDA, COVID-19, Vaccine

The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes.
  • Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.
  • The "Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market (5th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Rare Disorders, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musco-skeletal Disorders, Blood Disorders, Immunological Diseases, and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities.

Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs

Retrieved on: 
Monday, October 10, 2022
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Health Technology, Genetics, Other Health, CRL, Method, CA, ATMP, Efficiency, PST, GMP, NYSE, Patient, Clinic, Biotechnology, Drug development, Gene, Mesa, Research, Command and control, Senior advisor, Reception, Visions of the Future, Company, AAV, Doctor of Philosophy, Industry, CDMO, Gene therapy, Government, DNA, HEK293, Transfection, Vaccine, Fine chemical, Management, Pharmaceutical industry, Cell

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation Vector Platform (nAAVigation).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its nAAVigation Vector Platform (nAAVigation).
  • The nAAVigation platform has the capability to reduce a programs timeline to GMP for viral vector gene therapy developers by 55 percent, translating to fewer than eight (8) months compared to traditional manufacturing workflows.
  • Charles River will launch the nAAVigation platform approach and will highlight its benefits during a reception on October 12, during Cell and Gene Meeting on the Mesa , in Carlsbad, CA.
  • The launch of the nAAVigation Vector Platform process is the latest in a series of portfolio enhancements aimed at supporting our cell and gene therapy clients from early target identification through clinical-stage manufacturing.

Discovery Life Sciences Appoints Chief Scientific Officer to Drive Company's Rapid Global Expansion of Biomarker Services

Retrieved on: 
Thursday, September 29, 2022
Science, RUO, Precision medicine, Infection, Biomarker, Organization, Janssen Pharmaceuticals, Industry, CGT, Johnson & Johnson, Vertex Pharmaceuticals, Cancer, CEO, Oncology, Cell, Bristol Myers Squibb, LabCorp, Drug development, Gene therapy, Research, Multimedia, GMP, Management, Pharmaceutical industry, Vertex, Biological specimen, Discovery

HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.

Key Points: 
  • HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.
  • Dr. Platero brings over two decades of executive leadership in building and managing biomarker development organizations at leading pharmaceutical and diagnostics companies.
  • Before joining Discovery, Dr. Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals.
  • "Discovery is uniquely dedicated to providing scalable, end-to-end solutions for clients to accelerate their precision oncology programs," said Dr. Platero.

Discovery Life Sciences Appoints Chief Scientific Officer to Drive Company's Rapid Global Expansion of Biomarker Services

Retrieved on: 
Thursday, September 29, 2022
Science, RUO, Precision medicine, Infection, Biomarker, Organization, Janssen Pharmaceuticals, Industry, CGT, Johnson & Johnson, Vertex Pharmaceuticals, Cancer, CEO, Oncology, Cell, Bristol Myers Squibb, LabCorp, Drug development, Gene therapy, Research, GMP, Management, Medical imaging, Pharmaceutical industry, Vertex, Biological specimen, Discovery

HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.

Key Points: 
  • HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.
  • Dr. Platero brings over two decades of executive leadership in building and managing biomarker development organizations at leading pharmaceutical and diagnostics companies.
  • Before joining Discovery, Dr. Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals.
  • "Discovery is uniquely dedicated to providing scalable, end-to-end solutions for clients to accelerate their precision oncology programs," said Dr. Platero.

Optime Care Recognizes Gene Therapy and Specialty Pharmacy Awareness Month, September 2022

Retrieved on: 
Thursday, September 15, 2022
Medical Supplies, Health, Practice Management, Genetics, Other Health, Managed Care, Pharmaceutical, SHSMD, Accreditation Commission for Health Care, Salk Hall, URAC, Accreditation, Calendar, American Hospital Association, Company, Compliance, Degenerative disease, Partnership, Pharming, Patient, ACHC, Disorder, Gene therapy, Disease, Society, Pharmaceutical industry

Optime Care , a nationally recognized specialty pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces its support of the inaugural Gene Therapy and Specialty Pharmacy Awareness month , September 2022.

Key Points: 
  • Optime Care , a nationally recognized specialty pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces its support of the inaugural Gene Therapy and Specialty Pharmacy Awareness month , September 2022.
  • Optime Care, Inc. is a nationally recognized specialty pharmacy, distribution and patient management organization offering a suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders.
  • Our experience with small patient populations and our strategic partnership with AscellaHealth , enhances our services and ability to serve the specialty pharmacy market.
  • Optime Care has dual accreditation from the Utilization Review Accreditation Commission (URAC) for compliance with a specialty pharmacy and the Accreditation Commission for Health Care (ACHC) for specialty pharmacy services that demonstrate a commitment to providing quality care and services to consumers.

Juniper Biologics Establishes Global Headquarters in Singapore

Retrieved on: 
Thursday, September 15, 2022
Headquarters, Health, EDB, The Singapore Economic Review, Company, Acquisition, Degenerative disease, Patient, Economic Development Board, Quality of life, Science, Gene therapy, Hyundai, Sylvan, Pharmaceutical industry

SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by the Singapore Economic Development Board (EDB) who congratulated Juniper Biologics on the significance of this milestone. Juniper Biologics is backed by The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance.

Key Points: 
  • SINGAPORE, Sept. 15, 2022 /PRNewswire/ --Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations.
  • The establishment of its headquarters in Singapore is part of Juniper Biologics' commitment to Singapore and the wider region and will go towards supporting the company'splan to build out a patient-centric presence throughout key markets in the region and around the globe.
  • "Juniper Biologics' decision to establish its global headquarters in Singapore affirms and reflects our position as a leading hub for pharmaceutical companies looking to drive and grow their businesses in the region.
  • "Singapore is an excellent hub for Juniper Biologics to base our global operations, giving us the combination of easy access with strong reach to support our goal of bringing the next generation of medicines to patients throughout the region and beyond," said Raman Singh, Chief Executive Officer of Juniper Biologics.

Juniper Biologics Establishes Global Headquarters in Singapore

Retrieved on: 
Thursday, September 15, 2022
Headquarters, Health, EDB, The Singapore Economic Review, Company, Acquisition, Degenerative disease, Patient, Economic Development Board, Quality of life, Science, Gene therapy, Hyundai, Sylvan, Pharmaceutical industry

SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations. This announcement was supported by the Singapore Economic Development Board (EDB) who congratulated Juniper Biologics on the significance of this milestone. Juniper Biologics is backed by The Sylvan Group, an independent private equity investment firm focused on deep value companies with strong ESG-compliance.

Key Points: 
  • SINGAPORE, Sept. 15, 2022 /PRNewswire/ --Juniper Biologics, a science-led speciality healthcare company focused on commercialising novel therapies, today announced the establishment of its Global Headquarters in Singapore, from where the Company will continue the expansion of its global operations.
  • The establishment of its headquarters in Singapore is part of Juniper Biologics' commitment to Singapore and the wider region and will go towards supporting the company'splan to build out a patient-centric presence throughout key markets in the region and around the globe.
  • "Juniper Biologics' decision to establish its global headquarters in Singapore affirms and reflects our position as a leading hub for pharmaceutical companies looking to drive and grow their businesses in the region.
  • "Singapore is an excellent hub for Juniper Biologics to base our global operations, giving us the combination of easy access with strong reach to support our goal of bringing the next generation of medicines to patients throughout the region and beyond," said Raman Singh, Chief Executive Officer of Juniper Biologics.

CSL presents new research and development center in Marburg, Germany

Retrieved on: 
Tuesday, September 13, 2022
CSL, Plasma, ASX, United Nations Sustainable Development Group, Sustainable Development Goal 9, KfW, Carbon, Development, Haemophilia, Recycling, M600, A-DNA, Research, Canadian industrial research and development organizations, Nobel Prize, Goal, CSL Behring, Perreault, Growth, Calendar, Patient, Immunodeficiency, Natural Resources, Cell, Vaccine, Science, Ecosystem, Gene therapy, Biotechnology, R, Diphtheria, CSL Limited, Fine chemical, Renewable energy, Medicine

MARBURG, Germany, Sept. 13, 2022 /PRNewswire/ -- After three years of construction, global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), today, inaugurated its new EUR 150 million research and development (R&D) site on the grounds of the research campus in Marburg's Görzhausen Industrial Park. Covering around 40,000 square meters, the M600 R&D center provides space for up to 500 R&D employees, making it CSL's largest R&D center worldwide and combining all disciplines under one roof. 

Key Points: 
  • MARBURG, Germany, Sept. 13, 2022 /PRNewswire/ -- After three years of construction, global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), today, inaugurated its new EUR 150 million research and development (R&D) site on the grounds of the research campus in Marburg's Grzhausen Industrial Park.
  • Construction of CSL's new M600 research and development (R&D) center in Marburg, Germany, began in November 2019 and will be completed later this calendar year.
  • It will also provide space for around 500 CSL research and development employees as well as academic and cooperation partners.
  • Today, CSL including our three businesses, CSL Behring, CSL Seqirus, and CSL Vifor provides lifesaving products to patients in more than 100 countries and employs more than 30,000 people.